- Home
- IPSC vs CCEL Comparison
IPSC vs CCEL Comparison
Compare IPSC & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- CCEL
- Stock Information
- Founded
- IPSC 2019
- CCEL 1989
- Country
- IPSC United States
- CCEL United States
- Employees
- IPSC N/A
- CCEL N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- CCEL Managed Health Care
- Sector
- IPSC Health Care
- CCEL Health Care
- Exchange
- IPSC Nasdaq
- CCEL Nasdaq
- Market Cap
- IPSC 43.2M
- CCEL 34.8M
- IPO Year
- IPSC 2021
- CCEL 1997
- Fundamental
- Price
- IPSC $0.56
- CCEL $4.40
- Analyst Decision
- IPSC Strong Buy
- CCEL Strong Buy
- Analyst Count
- IPSC 5
- CCEL 1
- Target Price
- IPSC $3.33
- CCEL $8.50
- AVG Volume (30 Days)
- IPSC 486.6K
- CCEL 22.8K
- Earning Date
- IPSC 11-04-2025
- CCEL 10-15-2025
- Dividend Yield
- IPSC N/A
- CCEL 13.39%
- EPS Growth
- IPSC N/A
- CCEL N/A
- EPS
- IPSC N/A
- CCEL N/A
- Revenue
- IPSC $114,128,000.00
- CCEL $31,988,783.00
- Revenue This Year
- IPSC $1,589.94
- CCEL $1.75
- Revenue Next Year
- IPSC N/A
- CCEL N/A
- P/E Ratio
- IPSC N/A
- CCEL N/A
- Revenue Growth
- IPSC 5491.77
- CCEL 1.10
- 52 Week Low
- IPSC $0.34
- CCEL $4.09
- 52 Week High
- IPSC $1.83
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- IPSC 60.86
- CCEL 40.04
- Support Level
- IPSC $0.48
- CCEL $4.38
- Resistance Level
- IPSC $0.51
- CCEL $4.93
- Average True Range (ATR)
- IPSC 0.03
- CCEL 0.13
- MACD
- IPSC 0.01
- CCEL -0.03
- Stochastic Oscillator
- IPSC 67.79
- CCEL 4.80
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.